Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
1.100
-0.040 (-3.51%)
Mar 26, 2026, 11:49 AM EDT - Market open

RANI Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-54.54-56.58-67.88-63.34-53.09-16.7
Depreciation & Amortization
1.031.030.820.550.50.59
Stock-Based Compensation
16.0916.0319.0115.7822.6-
Other Adjustments
1.084.57-1.04-0.011.180.11
Change in Receivables
-0.6-----
Changes in Accounts Payable
0.710.71-0.60.160.540.93
Changes in Accrued Expenses
-0.360.35-0.540.610.74-0.64
Changes in Unearned Revenue
-----2.722.54
Changes in Other Operating Activities
-1.43-1.61-1.01-0.26-1.99-1.79
Operating Cash Flow
-34.24-35.5-51.24-46.52-32.25-14.96
Capital Expenditures
-0.3-0.27-1.23-1.62-0.51-1.2
Purchases of Investments
-50.16-57.47-73.26-73.82--
Proceeds from Sale of Investments
78.277.55104.353--
Investing Cash Flow
27.7419.8129.86-72.44-0.51-1.2
Short-Term Debt Issued
-----1.25
Short-Term Debt Repaid
-----1.25-
Net Short-Term Debt Issued (Repaid)
-----1.251.25
Long-Term Debt Issued
---29.57-2.78
Long-Term Debt Repaid
-7.5-5---3.31-
Net Long-Term Debt Issued (Repaid)
-7.5-5-29.57-3.312.78
Issuance of Common Stock
0.2118.630.40.3273.67-
Repurchase of Common Stock
-0.07-0.05-0.16-0.63--
Net Common Stock Issued (Repurchased)
0.1418.590.23-0.3173.67-
Issuance of Preferred Stock
----6.3268.49
Net Preferred Stock Issued (Repurchased)
----6.3268.49
Other Financing Activities
----0.261.720.16
Financing Cash Flow
9.7313.590.2329.0177.1572.68
Net Cash Flow
3.23-2.1-21.14-89.9544.456.52
Free Cash Flow
-34.54-35.76-52.47-48.13-32.75-16.16
FCF Margin
-2878.67%-3478.99%---1205.41%-3497.84%
Free Cash Flow Per Share
-1.14-1.26-2.06-2.02-1.68-0.34
Levered Free Cash Flow
-37.65-34.8-36.52-1.58-16.34-28.94
Unlevered Free Cash Flow
-51.64-53.1-68.65-63.94-55-16.08
Updated Nov 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q